{"title":"Anticancer effect of ethanolic extract of Rheum ribes L. rhizomes: assessment of dose and time-dependent effects in cell-based models","authors":"Zeina Nehme, Fatima Ghandour, Akram Hijazi, Mona Diab-Assaf, Racha Karaky","doi":"10.1007/s13596-024-00772-z","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Medicinal plants have been traditionally used in the treatment of various diseases including cancer, however, their IC<sub>50</sub> determined in vitro are hardly attained in patients. <i>Rheum ribes L</i>. is an indigenous medicinal plant shown to possess anticancer activity due to high polyphenolic compounds abundance. Our objective was to assess if long-term exposure to plant extract concentrations lower than IC<sub>50</sub> may still possess an anticancer potential.</p><h3>Methods</h3><p>We used the ethanolic extract of rhizomes of <i>Rheum ribes L.</i> (EERR) and assessed its effect on proliferation, clonogenicity, and senescence in cell lines-based models.</p><h3>Results</h3><p>Our results showed that EERR has a short-term antiproliferative activity on non-small cell lung carcinoma A549, breast cancer MCF7, and glioblastoma SF268 cell lines with IC<sub>50</sub> varying from 100 to 255 µg/mL. Additionally, EERR decreased the population doubling level and the clonogenic ability of the three cancer cell lines at lower concentrations (10 to 100 µg/mL) and with longer treatment protocols. This was accompanied by a significant increase in the senescence-associated β-galactosidase activity, suggesting that EERR induces senescence at these concentrations.</p><h3>Conclusion</h3><p>EERR displayed anticancer activity at concentrations 2- to 10-fold lower than the IC<sub>50</sub> in three different cancer cell lines and should be further investigated as it may provide novel therapeutic avenues for cancer treatment.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":7613,"journal":{"name":"Advances in Traditional Medicine","volume":"25 1","pages":"175 - 185"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Traditional Medicine","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s13596-024-00772-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Medicinal plants have been traditionally used in the treatment of various diseases including cancer, however, their IC50 determined in vitro are hardly attained in patients. Rheum ribes L. is an indigenous medicinal plant shown to possess anticancer activity due to high polyphenolic compounds abundance. Our objective was to assess if long-term exposure to plant extract concentrations lower than IC50 may still possess an anticancer potential.
Methods
We used the ethanolic extract of rhizomes of Rheum ribes L. (EERR) and assessed its effect on proliferation, clonogenicity, and senescence in cell lines-based models.
Results
Our results showed that EERR has a short-term antiproliferative activity on non-small cell lung carcinoma A549, breast cancer MCF7, and glioblastoma SF268 cell lines with IC50 varying from 100 to 255 µg/mL. Additionally, EERR decreased the population doubling level and the clonogenic ability of the three cancer cell lines at lower concentrations (10 to 100 µg/mL) and with longer treatment protocols. This was accompanied by a significant increase in the senescence-associated β-galactosidase activity, suggesting that EERR induces senescence at these concentrations.
Conclusion
EERR displayed anticancer activity at concentrations 2- to 10-fold lower than the IC50 in three different cancer cell lines and should be further investigated as it may provide novel therapeutic avenues for cancer treatment.
期刊介绍:
Advances in Traditional Medicine (ADTM) is an international and peer-reviewed journal and publishes a variety of articles including original researches, reviews, short communications, and case-reports. ADTM aims to bridging the gap between Traditional knowledge and medical advances. The journal focuses on publishing valid, relevant, and rigorous experimental research and clinical applications of Traditidnal Medicine as well as medical classics. At the same time, the journal is devoted to communication among basic researcher and medical clinician interested in the advancement of Traditional Medicine. Topics covered by the journal are: Medical Classics & History; Biomedical Research; Pharmacology & Toxicology of Natural Products; Acupuncture & Moxibustion; Sasang Constitutional Medicine; Diagnostics and Instrumental Development; Clinical Research. ADTM is published four times yearly. The publication date of this journal is 30th March, June, September, and December.